



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

APR - 5 2001

Mr. Michael Turanchik
Director, Research & Development
Medtox® Diagnostics, Inc.
1238 Anthony Road
Burlington, NC 27215

Re: 510(k) NUMBER: K010564
Trade/Device Name: Verdict® -II THC/COC/OPI/AMP/PCP/BAR/BZO
Profile® -II THC/COC/OPI/AMP/PCP/BAR/BZO
Verdict® -II THC/COC/BAR/BZO
Regulation Number: 862.3100
Regulatory Class: II
Product Code: DKZ, DIS, LDJ, DIO, DJG, JXM
Dated: February 21, 2001
Received: February 26, 2001

Dear Mr. Turanchik:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in dark ink, reading "Steven Gutman". The signature is written in a cursive style with a large, stylized "S" and "G".

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Attachment 2 (D)

Indications for Use Statement

510(k)
Number
(if known)

Device Name Verdict®-II THC/COC/OPI/AMP/PCP/BAR/BZO

Indications
for Use

Verdict®-II THC/COC/OPI/AMP/PCP/BAR/BZO is a one-step immunochromatographic test for the rapid qualitative detection of Cannabinoids (THC), cocaine, opiates, amphetamines, phencyclidine (PCP), barbiturates and benzodiazepines in human urine. The cutoffs of these drugs are at the following concentrations:

THC	Tetrahydrocannabinol	50 ng/mL
COC	Cocaine (Benzoylecgonine)	300 ng/mL
OPI	Opiates (Codeine/Morphine)	300 ng/mL
AMP	Amphetamine	1000 ng/mL
PCP	Phencyclidine	25 ng/mL
BAR	Barbiturates (Phenobarbital)	200 ng/mL
BZO	Benzodiazepines (Nordiazepam)	300 ng/mL

This product is not for over the counter sale.

Verdict®-II THC/COC/OPI/AMP/PCP/BAR/BZO provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED

(Division Sign-Off)

Division of Clinical Laboratory Sciences

510(k) Number

16564

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒
(Per 21 CFR 801. 109)

OR

Over-The-Counter Use ☐

Attachment 2 (E)

Indications for Use Statement

510(k)
Number
(if known)

Device Name Profile®-II THC/COC/OPI/AMP/PCP/BAR/BZO

Indications for Use

Profile®-II THC/COC/OPI/AMP/PCP/BAR/BZO is a one-step immunochromatographic test for the rapid qualitative detection of Cannabinoids (THC), cocaine, opiates, amphetamines, phencyclidine (PCP), barbiturates and benzodiazepines in human urine. The cutoffs of these drugs are at the following concentrations:

THC	Tetrahydrocannabinol	50 ng/mL
COC	Cocaine (Benzoylecgonine)	300 ng/mL
OPI	Opiates (Codeine/Morphine)	2000 ng/mL
AMP	Amphetamine	1000 ng/mL
PCP	Phencyclidine	25 ng/mL
BAR	Barbiturates (Phenobarbital)	200 ng/mL
BZO	Benzodiazepines (Nordiazepam)	300 ng/mL

This product is not for over the counter sale.

Profile®-II THC/COC/OPI/AMP/PCP/BAR/BZO provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED

Dean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices

510(k) Number

K010564

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒
(Per 21 CFR 801. 109)

OR

Over-The-Counter Use ☐

Attachment 2 (F)

Indications for Use Statement

510(k)
Number
(if known)

Device Name Verdict®-II THC/COC/BAR/BZO

Indications for Use

Verdict®-II THC/COC/BAR/BZO is a one-step immunochromatographic test for the rapid qualitative detection of cannabinoids (THC), cocaine, barbiturates and benzodiazepines in human urine. The cutoffs of these drugs are at the following concentrations:

THC	Tetrahydrocannabinol	50 ng/mL
COC	Cocaine (Benzoylecgonine)	300 ng/mL
BAR	Barbiturates (Phenobarbital)	200 ng/mL
BZO	Benzodiazepines (Nordiazepam)	300 ng/mL

This product is not for over the counter sale.

Verdict®-II THC/COC/BAR/BZO provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED

[Signature]
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K010564

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒
(Per 21 CFR 801.109)

OR

Over-The-Counter Use ☐